Prediction of response to tapentadol in chronic low back pain
Open Access
- 11 August 2016
- journal article
- research article
- Published by Wiley in European journal of pain
- Vol. 21 (2) , 322-333
Abstract
Background: Many chronic low back pain (cLBP) patients do not satisfactorily respond to treatment. The knowledge of responders and non‐responders before initiating treatment would improve decision making and reduce health care costs. The aims of this exploratory prediction study in cLBP patients treated with tapentadol were to identify predictors of treatment outcome based on baseline characteristics, to evaluate quality‐of‐life and functionality as alternative outcome parameters and to develop nomograms to calculate the individual probability of response.Methods: In a retrospective analysis of an open‐label phase 3b trial, 46 baseline characteristics were included into statistical prediction modelling. One hundred and twenty‐one patients were followed up during the titration and treatment period and 67 patients were analysed who discontinued the trial.Results: Demographic data were not relevant for response prediction. Nine baseline co‐variables were robust: painDETECT score, intensity of burning and painful attacks, SF36 Health Survey score (MCS, PCS), EuroQol‐5, Hospital Anxiety/Depression Scale. Gender had a minor influence. Alternative outcomes (quality‐of‐life, functionality) were more important for response prediction than conventional pain intensity measures. Neuropathic symptoms (high painDETECT score) had a positive predictive validity. Painful attacks and classical yellow flags (depression, anxiety) negatively influenced the treatment response. High depression scores, female gender and low burning predicted discontinuation during titration.Conclusion: In this exploratory study, predictive baseline characteristics have been identified that can be used to calculate the individual probability of tapentadol response in cLBP. The small sample size in relation to the number of initial variables is a limitation of this approach.Significance: Predictors for treatment response of tapentadol were identified in patients with chronic low back pain based on clinical pre‐treatment characteristics that can guide personalized treatment. Quality‐of‐life and functionality were the most relevant outcomes for response prediction.Keywords
Funding Information
- Medtronic
- Eisai
- Eli Lilly and Company
- Pfizer
- Genzyme
- Astellas Pharma US
- Allergan
- Boehringer Ingelheim
- Bayer
This publication has 31 references indexed in Scilit:
- Axial Low Back Pain: One Painful Area – Many Perceptions and MechanismsPLOS ONE, 2013
- Relationship of Negative Affect and Outcome of an Opioid Therapy Trial Among Low Back Pain PatientsPain Practice, 2012
- Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendationsPain, 2012
- Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b studyCurrent Medical Research and Opinion, 2012
- The Neuropathic Components of Chronic Low Back Pain: A Prospective Multicenter Study Using the DN4 QuestionnaireThe Journal of Pain, 2011
- Does Report of Craving Opioid Medication Predict Aberrant Drug Behavior Among Chronic Pain Patients?The Clinical Journal of Pain, 2009
- Pregabalin as a Treatment for Painful Diabetic Peripheral Neuropathy: A Meta-AnalysisRegional Anesthesia & Pain Medicine, 2008
- painDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurrent Medical Research and Opinion, 2006
- Comorbid Subjective Health Complaints in Low Back PainSpine, 2006
- The association between negative affect and opioid analgesia in patients with discogenic low back painPain, 2005